Sanofi bets $425M cash on a transformation-style next-gen vaccine deal — as the Big Pharma team makes a point
Back at the end of last March, with the world locking down in the face of a pandemic, Sanofi tied up with mRNA biotech Translate Bio an a hastily patched-up Covid-19 deal that came with no money down on top of their original pact.
Now, as new Sanofi CEO Paul Hudson plants the corporate flag on a quest to do a makeover of their slow-mo corporate image (see related story), Sanofi widened its embrace with another add-on: And this one comes with the considerable panache of a big upfront to cover a next-gen drug technology.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.